Review of the epidemiology and burden of ulcerative colitis in Latin America

Abstract

<jats:p> The incidence and prevalence of ulcerative colitis (UC) has been reported to be rising in newly industrialised regions, such as Latin America. Here, we review data from published studies reporting demographics and clinical aspects of UC in Latin America to further understand epidemiology and disease burden. The incidence and prevalence of UC in Latin America varied between regions and studies, ranging between 0.04 to 8.00/100,000 and 0.23 to 76.1/100,000, respectively, and generally increased over the period from 1986 to 2015. The majority of patients with UC were female (53.6–72.6%) and urban residents (77.8–97.4%). Extraintestinal manifestations were reported in approximately 26–89.4% of patients. Use of biologic therapies was generally low (0.8–16.2%), with the exception of Mato Grosso do Sul, Brazil, with a greater proportion of patients tending to receive 5-aminosalicylates, immunosuppressants or corticosteroids; colectomy rates varied between studies (1.5–22%). A high proportion of patients had moderate to severe UC (45.9–73.0%) and, in 11 of 19 studies, the greatest proportion of patients had extensive disease (pancolitis). Colorectal cancer (0–1.7%) and mortality rates (0–7.6%) were low. This evaluation of published studies may influence therapeutic approaches and the development of strategies to improve healthcare access and patient outcomes, although further high-quality studies are required in patients with UC in Latin America. </jats:p>

Incidence, Prevalence, and Epidemiological Characteristics of Inflammatory Bowel Diseases in the State of Paraná in Southern Brazil

“…In terms of the sex distribution of IBD, we found a higher prevalence among females compared to that among male, which is in line with the results of several previous studies, such as the one carried out by Souza in 2002 (7,10,(23)(24)(25) . However, across all the individual years observed during the study period (2010-2019), we found similar incidence rates for IBD between male and female patients.…”

Animal Models and Pathogenesis of Ulcerative Colitis

“…UC is an intractable, cancer-prone, refractory gastrointestinal disease, since Stephen et al first described the pathology of diseases such as colitis or idiopathic colitis [ 1 ]. In recent years, the incidence of the disease has been increasing, and it has been classified as one of the intractable diseases by the World Health Organization (WHO) [ 2 ]. Currently, there is no effective treatment for UC, and the current main treatment is also based on controlling the inflammatory response of the intestine and controlling complications.…”

Oral Core–Shell Nanoparticles Embedded in Hydrogel Microspheres for the Efficient Site-Specific Delivery of Magnolol and Enhanced Antiulcerative Colitis Therapy

“…Ulcerative colitis (UC), a kind of chronic nonspecific inflammatory bowel disease, mainly involves intestinal inflammation and epithelial injury, including the rectum, colonic mucosa, and submucosa, accompanied by some common colitis symptoms, i.e., rectal bleeding, diarrhea, abdominal pain, weight loss, and even increased colorectal cancer risk . Currently, the rise of global industrialization and the change in East–West dietary habits have been paralleled by a dramatic increase in the incidence of UC worldwide, resulting in a substantial burden on public healthcare .…”